C. Peiro et al., Pharmacological interference of vascular smooth muscle cell hypertrophy induced by glycosylated human oxyhaemoglobin, EUR J PHARM, 386(2-3), 1999, pp. 317-321
Nonenzymatically glycosylated human oxyhaemoglobin induces vascular smooth
muscle cell hypertrophy by releasing reactive oxygen species. We analysed t
he ability of drugs with antihypertrophic properties for the vascular wall
and/or antioxidant activity, such as captopril, losartan, and nifedipine, o
r gliclazide, carvedilol, and ascorbic acid, to interfere with 10 nM glycos
ylated human oxyhaemoglobin-induced increase in vascular smooth muscle cell
size (118 +/- 0.5% of basal). Vascular smooth muscle cell hypertrophy was
abolished concentration-dependently, with pD(2) values over a 100-fold inte
rval: 6.4 +/- 0.3, 7.7 +/- 0.4, 7.3 +/- 0.4, 7.4 +/- 0.6, 8.8 +/- 0.2, and
9.0 +/- 0.2 for captopril, losartan, nifedipine, ascorbic acid, carvedilol
and gliclazide, respectively. Drugs with powerful antioxidant properties, e
specially carvedilol and gliclazide, are particularly effective in preventi
ng glycosylated human oxyhaemoglobin-induced vascular smooth muscle cell hy
pertrophy. (C) 1999 Elsevier Science B.V. All rights reserved.